Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • ELISA
  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

phospho-4E-BP1 [pT46]

  • Product Code: X2009P
  • Size: 10 Miniblots
  • Price (USD): $562

Cat #

X2009P		 Quantity:      

Data Sheet

Product Name

phospho- 4E-BP1 [pT46]

Host/Source

Rabbit

Isotype

IgG

Product Type

Phosphorylation Site-Specific Antibody

Reactivity

Human, Mouse

Applications

Western Blot

Purification

Antigen Immunoaffiinity Purification

Size

10 Miniblots

Price (USD)

$562

Background

Eukaryotic initiation factor 4E binding protein 1 (4E-BP1), also known as PHAS, is a ~20 kDa member of a family of eIF4E-binding proteins whose binding affinity to eIF4E is regulated by its phosphorylation. It inhibits cap-dependent translation by binding to eIF4E on the same site that overlaps the binding site for eIF4G, preventing its binding to the latter and eventually leading to an increase in mRNA translation. The phosphorylatin of 4E-BP1 is critical in determining cell fate by controlling translation initiation and apoptotic potency. 4E-BP1 is hyperphosphorylated in response to several external stimuli including hormones, growth factors, mitogens, cytokines and G-protein–coupled receptors and in response to stress conditions including nutrient deprivation. The phosphorylation of 4E-BP1 increases in response to activated phosphoinositol 3’-kinase (PI-3K) or its downstream effector Akt/PKB. 4E-BP1 is believed to mediate PI-3K and FRAP/mTOR signaling and is phosphorylated on at least six serine and threonine sites (Thr 37, Thr 46, Ser 65, Thr 70, Ser 83, and Ser 112). The phosphorylation of these sites is believed to occur in an orderly fashion where phosphorylation of threonine 37 and 46 by FRAP/mTOR is a priming step for subsequent phosphorylation of 4E-BP1 at the carboxy-terminal sites.

Immunogen

Chemically synthesized phosphopeptide derived from the region of human 4E-BP1 that contains threonine 46. The sequence is conserved in human, mouse and rat.

Positive Control

NIH3T3 cell lysate

Formulation

Provided as solution in phosphate buffered saline, pH 7.3, with 1.0 mg/ml BSA and 0.05% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight

20 kDa

Product Image

Image Legend

Lysates prepared from NIH3T3 cells left untreated or treated with PI-3K inhibitor LY2904002 (lanes 2 & 3), prior to PDGF stimulation (lanes 1 & 3) and from EGF-treated HEK293 cells (4-8), Membranes were then left untreated (lanes 1-7) or treated with Lambda phosphatase (8), and incubated with 4E-BP1 [pT46] antibody for two hours at room temperature, following prior incubation with: no peptide (lanes 1 & 2), non-phosphopeptide corresponding to the immunogen (3), a generic phospho-threonine-containing peptide (4), or the phosphopeptide immunogen (5).

Database Links:

SwissProtQ60876Mouse
SwissProtQ13541Human

References

1. Stephens, L., et al. (2005) Phosphoinositide 3-kinases as drug targets in cancer.
Curr. Opin. Pharmacol. 5(4):357-365.
2. Zhou, L., et al. (2005) 4E-binding protein phosphorylation and eukaryotic initiation factor-4E release are required for airway smooth muscle hypertrophy. Am. J. Respir. Cell Mol. Biol. 33(2):195-202.
3. Greenberg, V.L. and S.G. Zimmer (2005) Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene 24(30):4851-4860.
4. Wang, X., et al. (2005) Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol. Cell Biol. 25(7):2558-2572.
5. Li, W. and B.E. Sumpio (2005) Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway. Am. J. Physiol. Heart Circ. Physiol. 288(4):H1591-H1597.
6. Li, S., et al. (2002) Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol. Cell Biol. 22(8):2853-2861.
7. Gingras, A.C., et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15(21):2852-2864.
8. Gingras, A.C., et al. (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13(11):1422-1437.